Please assess the completion status of the following clinical trial:

Trial Title: Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of advanced/metastatic lung cancer~Exclusion Criteria:~* Previous treatment with chemotherapy~* Uncontrolled diabetes~* History/active cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 2 (Arms A & B) (Type: EXPERIMENTAL): CP-751,871 + paclitaxel + carboplatin
- Phase 1b (Type: EXPERIMENTAL): 1. Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin~2. Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).